Taking and tracking your INQOVI

Taking INQOVI

How is INQOVI taken?

INQOVI tablets contain 35 mg of
decitabine and 100 mg of cedazuridine

Swallow the tablet whole, without cutting, crushing, or chewing it
Take INQOVI on an empty stomach at least 2 hours before or 2 hours after eating
If you vomit after taking a dose, do not take an additional dose, and take your next scheduled dose at your usual time

What to do if you miss a dose

If you miss your dose of INQOVI, take it within 12 hours of your usual time. If you miss your dose by more than 12 hours, skip that dose, take your next one at the usual time the next day, and add an extra day to your cycle.

How to safely store INQOVI

Keep it at room temperature between 68°F and 77°F (20°C and 25°C)
Keep it in its original packaging until use
Ask your healthcare team how to throw it away safely

Taking your medication as directed by your doctor is the best way to manage your AML or MDS, including CMML

When to take INQOVI plus venetoclax for AML

You can follow this schedule to make sure that you or the person you are caring for is taking INQOVI and venetoclax the right way.

Take INQOVI at approximately the same time each day
Take INQOVI on an empty stomach at least 2 hours before or 2 hours after eating
Take INQOVI and venetoclax at least 2 hours apart. It’s important that you do not take INQOVI and venetoclax at the same time

Everyone’s treatment is different. If this schedule is right for you, keep following it for as long as your doctor tells you to. Your doctor will monitor your progress, regularly checking your blood cell counts, and adjust your dosing if needed.

To find out more about taking venetoclax, please see venetoclax Prescribing Information.

When to take INQOVI for MDS, including CMML

You can follow this schedule to make sure that you or the person you are caring for is taking INQOVI the right way. It might take multiple cycles of treatment before INQOVI starts helping your MDS improve.

Take INQOVI at approximately the same time each day
Take INQOVI on an empty stomach at least 2 hours before or 2 hours after eating

Everyone's treatment is different. Talk to your doctor to find out if this schedule is right for you. Your doctor will monitor your progress, regularly checking your blood cell counts, and adjust your dosing if needed.

Possible Side Effects

See a list of the most common side effects associated with INQOVI treatment and tips on managing them.

Learn more about side effects

Support and Resources

Download helpful resources for managing treatment and find links to AML and MDS advocacy groups.

Explore available support

INDICATIONS AND IMPORTANT SAFETY INFORMATION

WHAT IS INQOVI?

INQOVI is a prescription medicine used:

to treat adults with myelodysplastic syndromes (MDS), including chronic myelomonocytic leukemia (CMML). Your healthcare provider will determine if INQOVI can treat your type of MDS
in combination with venetoclax to treat adults with newly diagnosed acute myeloid leukemia (AML) who:
- are 75 years of age or older, or
- have other medical conditions that prevent the use of standard chemotherapy

It is not known if INQOVI is safe and effective in children.

IMPORTANT SAFETY INFORMATION

INQOVI may cause serious side effects, including:

Low blood cell counts. Low blood counts (white blood cells, platelets, and red blood cells) are common with INQOVI but can also be serious and lead to infections that may be life-threatening. If your blood cell counts are too low, your healthcare provider may need to delay treatment with INQOVI, lower your dose of INQOVI, or in some cases, give you a medicine to help treat low blood cell counts. Your healthcare provider may need to give you antibiotic medicines to prevent or treat infections or fever while your blood cell counts are low. Your healthcare provider will check your blood cell counts before you start treatment and regularly during treatment with INQOVI.

Tell your healthcare provider right away if you get any of the following signs and symptoms during treatment with INQOVI:

fever
chills
body aches
tiredness
bruising more easily than usual

Before taking INQOVI, tell your healthcare provider about all of your medical conditions, including if you:

have kidney problems
are pregnant or plan to become pregnant. INQOVI can harm your unborn baby
Females who are able to become pregnant:
- Your healthcare provider will check to see if you are pregnant before you start treatment with INQOVI
- Use effective birth control during treatment with INQOVI and for 6 months after the last dose of INQOVI
Males with female partners who are able to become pregnant should use effective birth control during treatment with INQOVI and for 3 months after the last dose. Talk to your healthcare provider if you have questions about birth control options that are right for you.
are breastfeeding or plan to breastfeed. It is not known if INQOVI passes into breast milk. Do not breastfeed during treatment with INQOVI and for 2 weeks after your last dose of INQOVI

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. INQOVI may affect the way certain other medicines work and may cause side effects. Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.

If taking INQOVI in combination with venetoclax for AML, please refer to the venetoclax Medication Guide for additional information.

The most common side effects of INQOVI in adults with MDS or CMML include: low white blood cell count (leukopenia, neutropenia), low platelets in your blood (thrombocytopenia), low red blood cell count (anemia), tiredness, constipation, bleeding, muscle pain, pain or sores in your mouth or throat, joint pain, nausea, shortness of breath, diarrhea, rash, dizziness, fever with low white blood cell count (febrile neutropenia), swelling of arms or legs, headache, cough, decreased appetite, upper respiratory tract infection, pneumonia, and changes in liver function tests.

The most common side effects of INQOVI in adults with AML in combination with venetoclax include: low white blood cell counts (leukopenia, lymphocytopenia, neutropenia), low platelets in your blood (thrombocytopenia), fever with low white blood cell count (febrile neutropenia), bleeding, low red blood cell count (anemia), infection, diarrhea, tiredness, pain or sores in your mouth or throat, constipation, joint pain, decreased appetite, swelling of arms or legs, nausea, shortness of breath, sepsis, pneumonia, rash, changes in liver function tests, muscle pain, abnormal heart rhythm, stomach-area (abdomen) pain, dizziness or feeling lightheaded, and decreased kidney function.

INQOVI may affect fertility in men. Talk to your healthcare provider if this is a concern for you. These are not all of the possible side effects of INQOVI. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

If you are taking INQOVI in combination with venetoclax for AML, please refer to the venetoclax Medication Guide for additional information.

Please read the full Patient Information and discuss with your healthcare provider.

Taking and tracking your INQOVI

How is INQOVI taken?

INQOVI tablets contain 35 mg of
decitabine and 100 mg of cedazuridine

What to do if you miss a dose

How to safely store INQOVI

Taking your medication as directed by your doctor is the best way to manage your AML or MDS, including CMML

When to take INQOVI plus venetoclax for AML

When to take INQOVI for MDS, including CMML

Possible Side Effects

Support and Resources

INDICATIONS AND IMPORTANT SAFETY INFORMATION

WHAT IS INQOVI?

IMPORTANT SAFETY INFORMATION

INQOVI may cause serious side effects, including:

Choose when your patient will start INQOVI + venetoclax for AML

Print the calendar to help your patient get started

Choose when your patient will start INQOVI for MDS

Print the calendar to help your patient get started

Taking and tracking your INQOVI

How is INQOVI taken?

INQOVI tablets contain 35 mg ofdecitabine and 100 mg of cedazuridine

What to do if you miss a dose

How to safely store INQOVI

Taking your medication as directed by your doctor is the best way to manage your AML or MDS, including CMML

When to take INQOVI plus venetoclax for AML

When to take INQOVI for MDS, including CMML

Possible Side Effects

Support and Resources

INDICATIONS AND IMPORTANT SAFETY INFORMATION

WHAT IS INQOVI?

IMPORTANT SAFETY INFORMATION

INQOVI may cause serious side effects, including:

Choose when your patient will start INQOVI + venetoclax for AML

Print the calendar to help your patient get started

Choose when your patient will start INQOVI for MDS

Print the calendar to help your patient get started

INQOVI tablets contain 35 mg of
decitabine and 100 mg of cedazuridine